The reactions reported after the application of the Sputnik V vaccine against the coronavirus “were mild and moderate, did not require hospitalization and are within the normal parameters of any vaccine,” spokesmen for the Ministry of Health said today a few days after the start of the campaign immunization.
The health portfolio reported that there were 317 cases of mild reactions after vaccination, after the application of 32,013 doses of Russian Sputnik V among health personnel in Argentina, which were reported in the Federal Register of Nominal Vaccination (NoMiVac).
Sources from the Ministry of Health told Télam that the preparation of this type of study was foreseen within the strategic planning for monitoring events related to immunization.
This type of records and controls “is planned and thought in the strategic plan, and there is a registration system in the National Surveillance System. What was done, in this case, is to urge the jurisdictions and vaccination areas to recorded events such as pain at the vaccination site, low-grade fever, fever or muscle pain, “they added.
Finally, they explained that so far, “the records in Argentina are consistent with the phase 1 and 2 trials in Russia” and that “adverse adverse effects are as expected.”
They added that these mild adverse effects mentioned “appear within 24 hours of application of the vaccine and disappear between 24 and 48 hours after application.”
The distribution of the 300 thousand doses of the Sputnik V vaccine in the country concluded on Monday 28, in a campaign that required uninterrupted tasks for 24 hours and the use of hundreds of preservatives, tons of dry ice and a large number of trucks to start tomorrow a historic vaccination scheme for thousands of health workers in all provinces.
Within the framework of a “federal, equitable and proportional” design for assigning the doses to each province, the vaccination plan began on Tuesday, December 29 and, simultaneously, each jurisdiction began to develop the process under its own plan. of application of the doses.
On the same day the applications began, Agustina Bisio, Director of Drug Evaluation and Registries of the National Administration of Medicines, Food and Medical Technology (Anmat), assured that the documentation referring to Sputnik V that the agency received “is as detailed as that of the other investigations “, and he maintained that” the other vaccines that are being authorized in the world have more incidences of adverse events “than the one developed by Russia.
“Have confidence because we are here to take care of you,” said Bisio, and stressed that, in the case of Sputnik V, “the occurrence of events does not reach 1 percent,” while “the reports of the other vaccines have many adverse events, and more serious and with greater impact to 1 percent “.